Psychopharmacology in psychodermatology

Journal of Cutaneous Medicine and Surgery

Volumn 12, Issue 6, 2008, Pages 255-267

  Shukla, Rahul ^a,b,c   Sasseville, Denis ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; DOXEPIN; ESCITALOPRAM; FLUOXETINE; OLANZAPINE; PAROXETINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; PSYCHOTROPIC AGENT;

ACNE; AGITATION; ALLERGIC REACTION; ANORGASMIA; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; APPETITE DISORDER; ATRIOVENTRICULAR BLOCK; BEDTIME DOSAGE; BLURRED VISION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DELUSIONAL DISORDER; DEPRESSION; DIAPHORESIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; EXCITEMENT; FACE EDEMA; FATIGUE; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HIRSUTISM; HUMAN; HYPERTENSION; HYPNOSIS; INSOMNIA; INVOLUNTARY MOVEMENT; IRRITABILITY; LIBIDO; LIGHT HEADED; LOW DRUG DOSE; MENTAL DISEASE; MORNING DOSAGE; MOTOR DYSFUNCTION; MOUTH DISEASE; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; OBSESSIVE COMPULSIVE DISORDER; ORAL VESICULATION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; RHINITIS; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SOMNOLENCE; ST SEGMENT DEPRESSION; STEVENS JOHNSON SYNDROME; SWEATING; TARDIVE DYSKINESIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; URINE RETENTION; URTICARIA; VISUAL DISORDER; VOMITING; WEIGHT GAIN; XEROSIS; XEROSTOMIA; ANXIETY; COMPARATIVE STUDY; DELUSION; DERMATOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; PSYCHOSOMATIC DISORDER; TIME;

ANXIETY; DELUSIONS; DEPRESSION; DERMATOLOGY; HUMANS; MENTAL DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOPATHOLOGY; PSYCHOPHARMACOLOGY; PSYCHOPHYSIOLOGIC DISORDERS; PSYCHOTROPIC DRUGS; SKIN DISEASES; TIME FACTORS;

EID: 64049101396     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.07062     Document Type: Review

References (59)

1. Gupta MA, Gupta AK, Ellis CN, Koblenzer CS. Psychiatric evaluation of the dermatology patient. Dermatol Clin 2005;4:591-9.
2. Gupta MA, Gupta AK. Psychodermatology: an update. J Am Acad Dermatol 1996;34:1030-46.
3. Koo J. Psychodermatology: a practical manual for clinicians. Curr Prob Dermatol 1995;7:203-25.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-revised. 4th ed. Washington (DC): American Psychiatric Association; 2000.
5. Fried RG, Gupta MA, Gupta AK. Depression and skin disease. Dermatol Clin 2005;23:657-64.
6. Cotterill JA. Dermatologic non-disease: a common and potentially fatal disturbance of cutaneous body image. Br J Dermatol 1981; 104:611-9.
7. Mann J. The medical management of depression. N Engl J Med 2005;353:1819-34.
8. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
9. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000; 48:894-901.
10. Kroenke K, West SL, Swindle R, et al. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. JAMA 2001;286:2947-55.
11. Lee CS, Koo J. Psychopharmacologic therapies in dermatology: an update. Dermatol Clin 2005;23:735-44.
12. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58 Suppl 13:23-9.
13. Balon R. SSRI-associated sexual dysfunction. Am J Psychiatry 2006; 163:1504-9.
14. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61 Suppl 11:37-41.
15. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997;58:291-7.
16. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87.
17. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11 Suppl 5:31-61.
18. Rosenbaum JF, Tollefson GD. Fluoxetine. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 237-46.
19. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34: 262-5.
20. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59 Suppl 15:19-27.
21. Fairbanks JM, Gorman JM. Fluvoxamine. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 283-90.
22. Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997;44: 495-8.
23. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-21.
24. MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 2001;7:1-24.
25. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999;46:839-49.
26. Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001;11:275-83.
27. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997; 43:619-26.
28. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001;35:1608-13.
29. Laurencic G, Malone DA Jr. Side effects of antidepressants: an overview. Cleve Clin J Med 2006;73:351-3.
30. Hudziak JJ, Rettew DC. Bupropion. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 327-39.
31. Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985;12:669-75.
32. Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin 2001;19:179-97, x.
33. Navi D, Koo J. Safety update on commonly used psychotropic medications in dermatology. J Drugs Dermatol 2006;5:109-15.
34. Koo JYM, Lee CS. Psychotropic agents. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy, 1st ed. Philadelphia: WB Saunders; 2001. p. 402-25.
35. Koenig TW, Garnis-Jones S, Rencic A, Tausk FA. Psychological aspects of skin diseases. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's dermatology, 6th ed. New York: McGraw-Hill Professional; 2003. p. 389-99.
36. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162-71.
37. Gupta MA, Gupta AK. The use of psychotropic drugs in dermatology. Dermatol Clin 2000;18:711-25, x.
38. Knowles SR, Shapiro LE, Shear NH. Drug interactions of clinical significance for the dermatologist. Am J Clin Dermatol 2003; 4:623-39.
39. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006; 51(8 Suppl 2):51S-5S.
40. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002;63 Suppl 8:17-23.
41. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17: 65-9.
42. Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005;66:94-9.
43. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004;161:1642-9.
44. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000;283:3082-8.
45. Koo JYM, Ham A. Psychocutaneous diseases. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. Spain: Mosby; 2003. p. 111-21.
46. Ninan PT, Muntasser S. Busiprone and gepirone. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 391-421.
47. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2006.
48. Koblenzer CS. Psychiatric syndromes of interest to dermatologists. Int J Dermatol 1993;32:82-8.
49. Blier P, Habib R, Flament MF. Pharmacotherapies in the management of obsessive-compulsive disorder. Can J Psychiatry 2006;51:417-30.
50. Murase JE, Wu JJ, Koo J. Morgellons disease: a rapport-enhancing term for delusions of parasitosis. J Am Acad Dermatol 2006;55: 913-4.
51. Lorenzo CR, Koo J. Pimozide in dermatologic practice: a comprehensive review. Am J Clin Dermatol 2004;5:339-49.
52. Desta Z, Kerbusch T, Soukhova N, et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998;285: 428-37.
53. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
54. Meehan WJ, Badreshia S, Mackley CL. Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol 2006;142: 352-5.
55. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by two human CYP 2D6 and YP3A4 enzymes. Drug Metab Dispos 2001;29: 1263-8.
56. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003;17: 517-38.
57. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000;22: 481-5.
58. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
59. Litt JZ. Litt's drug eruption reference manual. 13th ed. London: Informa Healthcare; 2007.